FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Senate Democrats Caution FDA on Mifepristone Review

Senate Democrats say they are worried that FDA and HHS may rely on partisan junk science during its recently announced review of the existing safety a...

latest-news-card-1
Human Drugs

FDA Posts Biohaven Troriluzole Complete Response Letter

FDA publicly releases an 11/4 complete response letter issued to Biohaven on its NDA seeking approval for troriluzole to treat spinocerebellar ataxia.

latest-news-card-1
Human Drugs

FDA Extends Review of Rhythms Setmelanotide sNDA

FDA extends by three months its review of Rhythm Pharmaceuticals supplemental NDA for Imcivree (setmelanotide) and its use in treating acquired hypoth...

latest-news-card-1
Human Drugs

Baxter Oncology FDA-483 Out

FDA releases the form FDA-483 with six observations from an inspection at the Baxter Oncology drug manufacturing facility in Halle, Westfalen, Germany...

Human Drugs

76 New or Revised Product-Specific Guidances Out

FDA publishes 76 new and revised product-specific guidances intended to speed generic drug development and approval.

latest-news-card-1
Human Drugs

White House Inks Deals with Lilly and Novo Nordisk

The Trump Administration announces new agreements with Eli Lilly and Novo Nordisk to lower U.S. prices for several products, including the GLP-1 medic...

latest-news-card-1
Human Drugs

6 Additional National Priority Vouchers Awarded

FDA announces six additional drugs awarded Commissioners National Priority vouchers.

latest-news-card-1
Human Drugs

18 Web Sites Warned About Illegal Botox Sales

FDA warns 18 Internet companies that they are illegally selling Botox products.

latest-news-card-1
Human Drugs

OAC Survey Calls for FDA Action on Obesity Drug Testing, Labeling

An Obesity Action Coalition survey finds that people want FDA and drug companies to change the way that obesity drugs are tested and labeled.

latest-news-card-1
Human Drugs

FDA Approves Caplyta for Major Depressive Disorder

FDA approves an expanded use for Johnson & Johnsons Caplyta (lumateperone) as an adjunctive therapy with oral antidepressants in adults with major dep...